RedHill Biopharma AI Stock Analysis
Want to see RDHL full AI Analyst Report?
RedHill Biopharma (RDHL) AI Stock Analysis
RedHill Biopharma
(NASDAQ:RDHL)
The company faces severe financial distress with collapsed revenues and persistent cash burn, which is the primary driver of the low score. Technical trends confirm sustained bearish momentum, and negative earnings render valuation metrics meaningless. The stock carries extreme risk.
RedHill Biopharma (RDHL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.15M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.08M
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.94
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
RedHill Biopharma Business Overview & Revenue Model
Company Description
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioi...
RedHill Biopharma Financial Statement Overview
Summary
Financial performance is critically weak. Revenue has collapsed to near zero, operating losses persist, and cash burn remains severe. Although debt has been reduced, the thin equity base and lack of operational income create an existential risk.
Income Statement
15Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 286.00K | 8.04M | 6.53M | 61.80M | 85.76M |
| Gross Profit | 0 | 286.00K | 4.85M | 3.07M | 28.46M | 36.35M |
| EBITDA | -3.97M | -7.65M | -7.59M | 26.27M | -22.18M | -63.03M |
| Net Income | -6.10M | -429.00K | -8.27M | 23.92M | -71.67M | -97.74M |
Balance Sheet | ||||||
| Total Assets | 26.27M | 25.34M | 18.04M | 23.05M | 158.87M | 181.19M |
| Cash, Cash Equivalents and Short-Term Investments | 5.16M | 3.97M | 4.62M | 6.36M | 19.98M | 38.00M |
| Total Debt | 1.07M | 1.07M | 356.00K | 1.17M | 122.69M | 87.81M |
| Total Liabilities | 27.35M | 21.08M | 22.73M | 20.98M | 207.27M | 172.31M |
| Stockholders Equity | -1.08M | 4.27M | -4.68M | 2.07M | -48.40M | 8.88M |
Cash Flow | ||||||
| Free Cash Flow | -4.58M | -9.66M | -9.38M | -35.83M | -29.38M | -65.16M |
| Operating Cash Flow | -4.56M | -9.65M | -9.37M | -35.82M | -29.18M | -65.05M |
| Investing Cash Flow | 372.00K | 1.69M | -9,000 | 3,989 | 8.30M | -8.14M |
| Financing Cash Flow | 5.38M | 7.32M | 8.42M | 21.38M | 11.45M | 73.46M |
RedHill Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDHL, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.43, below the 50-day MA of 0.51, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 34.44 is Neutral, neither overbought nor oversold. The STOCH value of 10.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RDHL.
RedHill Biopharma Risk Analysis
RedHill Biopharma disclosed 86 risk factors in its most recent earnings report. RedHill Biopharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksRedHill Biopharma Peers Comparison
Overall Rating
IRWD72Outperform
TAK67Neutral
TEVA65Neutral
SIGA54Neutral
PRGO52Neutral- RDHL37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IRWD | 72Outperform | $796.30M | 5.38 | -93.40% | ― | 18.09% | 403.76% |
| TAK | 67Neutral | $65.87B | 27.66 | 5.07% | 3.38% | 0.67% | -12.01% |
| TEVA | 65Neutral | $49.58B | 101.81 | 9.18% | ― | 2.99% | -28.63% |
| SIGA | 54Neutral | $224.91M | 490.62 | 0.42% | ― | -69.60% | -99.10% |
| PRGO | 52Neutral | $2.34B | -1.30 | -68.13% | 7.01% | -4.45% | -3289.03% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| RDHL | 37Underperform | $3.33M | -0.37 | -438.17% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RDHL | RedHill Biopharma Ltd | 0.38 | -0.69 | -64.39% | |
| IRWD | Ironwood Pharmaceuticals | 4.85 | 1.71 | 54.46% | |
| PRGO | Perrigo Company | 16.18 | 3.59 | 28.49% | |
| SIGA | Siga Technologies | 2.89 | -2.42 | -45.54% | |
| TEVA | Teva Pharmaceutical Industries Limited | 43.24 | 17.24 | 66.31% | |
| TAK | Takeda Pharmaceutical Company | 20.84 | 6.55 | 45.84% |
RedHill Biopharma Corporate Events
RedHill Biopharma Reports RHB-204 MAP-Killing Confirmation
RedHill Biopharma is a specialty biopharmaceutical company developing oral antimicrobial therapies, including RHB-204 and RHB-104, with a focus on MAP-related Crohn’s disease and mycobacterial infections. Its lead RHB-204 is a fixed-dose combination...
RedHill Biopharma Regains Global Rights to RHB-102 After Hyloris Deal Termination
On October 15, 2026, RedHill Biopharma terminated its License & Development Agreement with Hyloris Pharmaceuticals covering exclusive rights to RHB-102 outside North America, a deal originally signed in February 2025. As part of the mutual terminatio...
RedHill Biopharma Backs $2.9 Million NCI-Funded Opaganib–CAR T Trial in Ultra-High-Risk Myeloma
On October 19, 2026, RedHill Biopharma announced that its partner, the University of Oklahoma, received a five-year $2.9 million grant from the National Cancer Institute to clinically evaluate opaganib in combination with CAR T-cell therapy in ultra-...
RedHill Biopharma Expands U.S. ATM ADS Offering With New Prospectus Supplement
On October 13, 2026, RedHill Biopharma filed a prospectus supplement in the United States to increase the maximum aggregate amount of American Depositary Shares that can be sold under its existing at-the-market offering agreement with H.C. Wainwright...
RedHill Biopharma Wins Nasdaq Bid-Price Compliance Extension to April 2027
On October 6, 2026, RedHill Biopharma reported it received a notification from Nasdaq granting an additional 180 days, until April 5, 2027, to regain compliance with the exchange’s $1.00 minimum bid price requirement for its American Depositary Share...
RedHill Biopharma Reshapes GI Portfolio With Asset Sale and New Licensing Deals
On August 27, 2026, RedHill Biopharma completed the sale of its 70% stake in Talicia Holdings Inc. to a subsidiary of Apotex Health Corp. for an upfront $18 million and up to $35 million in potential milestone payments tied to worldwide net sales. Th...
RedHill Biopharma Reshapes GI Portfolio With Rebyota, Clenpiq Deal and Talicia Sale
RedHill Biopharma reported on September 30, 2026 that it has executed a full strategic portfolio reset, transforming itself into a more focused commercial GI player centered on Rebyota and Clenpiq. The company paid Ferring Pharmaceuticals $12 million...
RedHill Biopharma Inks 13-Year Global Deal for Ferring’s Rebyota and U.S. Rights to Clenpiq
On September 1, 2026, RedHill Biopharma said it had completed a major strategic shift in its GI business by divesting its Talicia product and redeploying $12 million of the $18 million proceeds to acquire exclusive global commercialization rights to...
RedHill Biopharma Sells Talicia Stake to Apotex for $18 Million Upfront
RedHill Biopharma, a specialty biopharmaceutical company focused on U.S. development and commercialization of gastrointestinal, infectious disease and oncology drugs, has built a late-stage pipeline that includes oral agents such as opaganib, RHB-102...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026